Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics Inc (NASDAQ: INTS) is a clinical-stage biotechnology company pioneering novel intratumoral therapies designed to combat solid tumors through localized drug delivery and immune system activation. This news hub provides investors and industry professionals with timely, comprehensive updates on the development of INTS's innovative cancer treatments.
Access authoritative information about clinical trial progress, regulatory developments, and scientific advancements related to the company's DfuseRx technology platform. Our curated collection features essential updates including trial result announcements, partnership agreements, and research publications - all critical for evaluating INTS's position in the competitive oncology therapeutics market.
Key content categories include updates on INT230-6 clinical programs, technological enhancements to tumor saturation methods, and strategic collaborations with leading cancer research institutions. The resource serves as both a historical archive and real-time monitoring tool for tracking the company's progress in developing treatments for soft tissue sarcoma, triple-negative breast cancer, and other challenging malignancies.
Bookmark this page for streamlined access to verified information about INTS's scientific developments and corporate milestones. Check back regularly for objective reporting on how the company's localized treatment approach could potentially reshape cancer care paradigms while maintaining focus on patient safety outcomes.
Intensity Therapeutics presented promising results from the INVINCIBLE study at the San Antonio Breast Cancer Symposium. In this Phase 2 trial, the drug INT230-6 achieved up to 100% tumor necrosis in patients with early-stage breast cancer, demonstrating significant immune response activation. The study involved 91 participants and highlighted INT230-6's potential as a pre-surgical treatment with manageable adverse effects. The data is bound to impact future cancer therapy approaches and reinforces the company's pioneering position in immune-based cancer treatments.
Intensity Therapeutics announced data from its ongoing Phase 1/2 study of INT230-6 presented at the CTOS Annual Meeting. Preliminary findings indicate that administering INT230-6 either alone or in combination with ipilimumab improves median overall survival (mOS) in patients with refractory sarcomas. Patients receiving a cumulative dose equivalent to 40% or more of their tumor burden exhibited an mOS of 715 days, compared to historical controls at 205 days. The results suggest favorable safety, supporting the potential of INT230-6 in treating metastatic sarcomas.
Intensity Therapeutics announced promising results from its phase 1/2 trial involving the cancer treatment INT230-6. Patients receiving INT230-6 alone had a median overall survival (mOS) of 373 days, significantly longer compared to historical data. In combination with pembrolizumab, the mOS was 205 days in a heavily pretreated patient group. The treatment has shown good tolerability and efficacy, inducing both tumor cell death and immune activation. Results will be presented at the SITC Annual Meeting, indicating ongoing research towards potential commercialization.
Intensity Therapeutics announced positive data from the INVINCIBLE study, showcasing significant tumor necrosis in early-stage breast cancers resistant to chemotherapy. The trial utilized INT230-6, which demonstrated up to 100% necrosis from a single injection, alongside increased immune cell activity in the tumor microenvironment. No surgical procedures were canceled or delayed due to the treatment. Results will be presented at the 2022 SITC Annual Meeting, indicating INT230-6's potential to alter treatment paradigms for patients awaiting surgery.
FAQ
What is the current stock price of INTENSITY THERAPEUTICS (INTS)?
What is the market cap of INTENSITY THERAPEUTICS (INTS)?
